Initiatives Showcase Commitment to Shaping the Future of Eye Health
SAN RAMON, CALIF., 4 September 2023—CooperVision’s global leadership in advancing myopia control and management as standard of care across all ocular health sectors will be in the spotlight at the 2023 European Society of Cataract and Refractive Surgeons (ESCRS) conference. The annual event is expected to draw thousands of ophthalmology clinicians, researchers, and educators to Vienna this week.
The company’s involvement begins on 7 September with a thought leadership panel at the pre-conference Ophthalmology Futures Forum moderated by Marcus Ang, MBBS, PhD, and Ian Flitcroft, DPhil, FRCOphth. Elizabeth Lumb, BSc (Hons) MCOptom, FBCLA, Director of Global Professional Affairs, Myopia Management, CooperVision, will join several industry and clinical colleagues to debate Myopia in the Digital Age, Is Technology the Answer? The discussion is scheduled to begin at 1400 CET at the Hilton Danube Waterfront.
The World Society of Paediatric Ophthalmology and Strabismus’ (WSPOS) Subspecialty Day, sponsored in part by CooperVision, will take place on 8 September. Correction and Control; The Value of Optical Interventions in Myopia Control, will also be led by Lumb. She will engage Ian Flitcroft, whose clinical research pursuits are known worldwide, on his latest explorations regarding evidence-base in respect of low dose atropine and the broader consideration of a clinical management plan in addressing myopia in Western verses Asian populations.
“The global scale of the myopia challenge and the availability of both optical and pharmacological treatments means that this isn’t a question of ophthalmology or optometry, but of cooperation and partnership,” said Flitcroft regarding his vision for the future of myopia management.
“Our engagement with the ophthalmology community through initiatives such as ESCRS underscores CooperVision’s unwavering dedication to advancing ocular health through evidence-based approaches in managing myopia progression.,” said Lumb. “Ophthalmology and the entire eye care professional community play an essential role in fostering innovation, uncovering insights, and contributing to the future of myopia control and management—outcomes we are proud to facilitate and amplify.”
Now prescribed in more than 30 countries, CooperVision’s MiSight® 1 day is clinically proven and indicated to slow the progression of myopia in children.1* The company also offers a range of orthokeratology contact lens designs and a spectacle lens with with Diffusion Optics Technology™ for myopia management.** For more information on the Opthalmology Futures Forum, including free registration to view the panels online, visit www.ophthalmology-futures.com.
# # #
U.S. Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.
China Indications for Use: MiSight® 1 day is indicated for the correction of myopia for patients with non-diseased phakic eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 D to -4.00 D with ≤ 0.75 diopters of astigmatism. It has the dual focal design with alternative multiple rings, which allows part of the light passing through the optical zone to focus in front of the retina, forming myopic defocus with the expectation to slow the change of axial length of the patients. Fitting and evaluation of the product should be in medical institutions by ophthalmologists with an intermediate title or above and with regular monitoring. It must be used in strict accordance with the IFU requirements.
*Compared to a single vision 1-day lens over a 3-year period.
** Spectacles with Diffusion Optics Technology™ are not approved for sale or distribution in every country worldwide.
1 Chamberlain P, Peixoto-de-Matos SC, Logan NS, Ngo C, Jones D, Young G. A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control. Optom Vis Sci. 2019 Aug;96(8):556-567.
About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia, and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit www.coopervision.com.
About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com
Media Contact
Laura DiCaprio, Senior Counselor
McDougall Communications for CooperVision
Laura@mcdougallpr.com or +1-585-545-1815